Abstract
Breast cancer(BC) is the most frequent neoplasm in women of the west countries. The treatment of BC is very complex, and include the combination of surgery, chemotherapy, radiotherapy, hormone therapy and immunotherapy. Surgery is the gold standard in the radical treatment of BC. Anthracyclines and taxanes are very important in the adjuvant treatment of BC. These drugs have shown an increased disease-free-survival and overall survival in several studies. Tamoxifen has been the gold standard adjuvant hormone therapy for the treatment of postmenopausal women with hormone-receptor-positive early BC for many years, but the third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are now recommended as the preferred therapy. Trastuzumab in combination with adjuvant chemotherapy has changed the natural history of early Her-2 positive BC. New drugs are under investigation in the treatment of BC.
MeSH terms
-
Anthracyclines / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Aromatase Inhibitors / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / radiotherapy
-
Breast Neoplasms / surgery
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / radiotherapy
-
Carcinoma, Ductal, Breast / surgery
-
Chemotherapy, Adjuvant*
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Estrogen Receptor Modulators / therapeutic use
-
Estrogens
-
Female
-
Humans
-
Immunotherapy
-
Mastectomy / methods
-
Neoplasms, Hormone-Dependent / drug therapy
-
Neoplasms, Hormone-Dependent / surgery
-
Radiotherapy, Adjuvant
-
Taxoids / therapeutic use
-
Trastuzumab
Substances
-
Anthracyclines
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Estrogen Receptor Modulators
-
Estrogens
-
Taxoids
-
Trastuzumab